You are here

  • Home
  • Archive
  • Volume 76, Issue Suppl 2
  • FRI0449 Analysis of the canadian adalimumab post-marketing observational epidemiological study assessing effectiveness in ankylosing spondylitis (complete-as): association between baseline extra articular manifestations and patient-reported outcomes

Article metrics

Article menu

Download PDFPDF

Poster Presentations
Spondyloarthritis - clinical aspects (other than treatment)
FRI0449 Analysis of the canadian adalimumab post-marketing observational epidemiological study assessing effectiveness in ankylosing spondylitis (complete-as): association between baseline extra articular manifestations and patient-reported outcomes
Free

 

Online download statistics by month:

Online download statistics by month: June 2017 to March 2024

AbstractFullPdf
Jun 2017300
Jul 2017200
Aug 2017402
Sep 2017801
Oct 20171102
Nov 20171200
Dec 20171000
Jan 20181003
Feb 2018802
Mar 20181000
Apr 20182003
May 20183602
Jun 20181202
Jul 2018800
Aug 2018400
Sep 2018200
Oct 20181403
Nov 2018602
Dec 20181000
Jan 2019401
Feb 2019200
Mar 2019201
Apr 2019403
May 2019202
Jun 2019200
Jul 2019200
Oct 2019202
Dec 2019001
Jan 2020400
Feb 2020001
Mar 2020001
Apr 2020001
May 2020602
Jun 2020402
Jul 2020601
Aug 2020201
Sep 2020800
Oct 2020201
Nov 2020200
Dec 2020401
Feb 2021202
Mar 2021002
Apr 2021402
May 2021004
Jun 2021002
Jul 2021001
Sep 2021005
Oct 202111014
Nov 202114011
Dec 20211201
Jan 2022601
Feb 2022200
Mar 2022102
Apr 2022402
May 20221206
Jun 20222802
Jul 2022401
Aug 2022606
Sep 2022207
Oct 2022404
Nov 20221001
Dec 2022601
Jan 2023202
Feb 2023200
Mar 20231000
Apr 2023200
May 2023003
Jun 2023201
Jul 2023504
Aug 2023302
Oct 2023201
Nov 20232055
Dec 20231001
Jan 2024401
Feb 2024201
Mar 2024200
Total4240191